Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oxford BioMedicaOXBDF 72 3-1 Month Momentum % is 3.71% as of Jul. 18, 2026. GuruFocus rates OXBDF with a GF Score™ of 72/100 and a GF Value™ of $6.73 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 1,389 Biotechnology companies, Oxford BioMedica ranks better than 68.54% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-18), Oxford BioMedica's 3-1 Month Momentum % is 3.71%.
The industry rank for Oxford BioMedica's 3-1 Month Momentum % or its related term are showing as below:
OXBDF's 3-1 Month Momentum % is ranked better than 68.54% of 1389
companies
in the Biotechnology industry
Industry Median: -13.25
vs OXBDF: 3.71
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Oxford BioMedica 3-1 Month Momentum % Related Terms
OXBDF vs VRTX, REGN, ALNY: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Oxford BioMedica's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxford BioMedica 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oxford BioMedica's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Oxford BioMedica's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oxford BioMedica (OXBDF) has a 3-1 Month Momentum % of 3.71% as of Jul. 18, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Oxford BioMedica and its competitors. According to the industry distribution chart, Oxford BioMedica ranks #437 out of 1389 companies in the Biotechnology industry, placing it in the top 31.5%.
Is Oxford BioMedica's 3-1 Month Momentum % too high?
Oxford BioMedica's current 3-1 Month Momentum % is 3.71%. Based on the distribution chart, Oxford BioMedica ranks #437 out of 1389 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Oxford BioMedica has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oxford BioMedica's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oxford BioMedica ranks #437 out of 1389 companies for 3-1 Month Momentum %. This puts Oxford BioMedica in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Oxford BioMedica and its competitors. Oxford BioMedica's current 3-1 Month Momentum % is 3.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioMedica stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioMedica (OXBDF) is currently considered Modestly Overvalued. The stock's GF Value™ is $6.73, compared to a current price of $7.99 — trading 18.7% above its estimated fair value. The current 3-1 Month Momentum % is 3.71%. Oxford BioMedica's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Oxford BioMedica (OXBDF), the current 3-1 Month Momentum % is 3.71% as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oxford BioMedica (OXBDF) Overvalued in 2026?
Based on GuruFocus' analysis, Oxford BioMedica stock appears to be overvalued.
The current stock price of $7.99 is trading 18.7% above its estimated GF Value™ of $6.73.
GuruFocus considers Oxford BioMedica to be Modestly Overvalued.
Key valuation signals for OXBDF:
3-1 Month Momentum %: 3.71%
GF Value™: $6.73 vs. price of $7.99 (18.7% above fair value)
No single metric tells the full story. See the OXBDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
72GF Score
Get the complete analysis for OXBDF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OXBDF has been successfully added to your 
